Epilepsy in Neurofibromatosis 1

Abstract

Neurofibromatosis 1 is the most common neurocutaneous disease. Neurologic manifestations are mainly represented by tumors such as optic gliomas, focal areas of high T₂-weighted signal known as unidentified bright objects, and mental retardation or learning disabilities. The prevalence of seizures has been reported to range from 3.8 to 6%. In the present study, we evaluated prevalence, type, and etiology of epilepsy in a neurofibromatosis 1 population. A retrospective analysis of 198 patients affected by neurofibromatosis 1 was performed. Fourteen patients (7%) were found to be epileptic. Every patient underwent electroencephalographic examination and neuroimaging investigations. Thirteen were submitted to magnetic resonance imaging (MRI) study and one to computed tomographic (CT) scanning. Single-photon emission computed tomographic and positron emission tomographic studies were performed in a few selected cases. Seizures were partial in 12 of these (85%) and generalized in 2 (15%). In nine (64%), epilepsy was secondary to brain lesions: five of these had cerebral tumors (three with epilepsy as the first symptom), three had cortical malformation, and one had mesial temporal sclerosis. Seizures were controlled rapidly in eight (57%) and drug resistant in four (29%). Two patients were lost at follow-up. All patients with uncontrolled seizures had severe mental retardation, and three of these had malformations of cortical development. Our observations and our re-evaluation of the literature indicate that patients with neurofibromatosis 1 have an increased risk of epilepsy related to intracranial masses and cytoarchitectural abnormalities, and seizures can represent the first symptom of a tumor or cortical malformation. Brain MRI and, in selected cases, functional studies appear to be useful in patients with neurofibromatosis 1 who present with seizures, especially if associated with mental retardation. (J Child Neurol 2003;18:338—342).

Get full access to this article

View all access options for this article.

References

Riccardi VM : Von Recklinghausen neurofibromatosis. N Engl J Med 1989;305:1617—1622.

Riccardi VM : Neurofibromatosis. Phenotype, Natural History, and Pathogenesis. Baltimore, Johns Hopkins University Press , 1992.

Friedman JM : Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1—6.

National Institutes of Health Consensus Development Conference : Neurofibromatosis. Conference statement. Arch Neurol 1988;45:575—578.

North KN : Neurofibromatosis 1 in children. Semin Pediatr Neurol 1998;5:231—242.

Cawthon RM , Weiss M. , Xu G. , et al: A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990;62:193—201.

Gutmann DH , Wood DL , Collins FS : Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A 1991;88:9658—9662.

Carey JC , Viskochil DH : Neurofibromatosis type 1: A model condition for the study of the molecular basis of variable expressivity in human disorders. Am J Med Genet 1999;89:7—13.

Korf BR , Carranzana E. , Holmes GL : Patterns of seizures observed in association with neurofibromatosis 1. Epilepsia 1993;34:616—620.

10.

Kulkantrakorn K. , Geller TJ : Seizures in neurofibromatosis 1. Pediatr Neurol 1998;19:347—350.

11.

Kotagal P. , Rothner D. : Epilepsy in the setting of neurocutaneous syndromes. Epilepsia 1993;34:71—78.

12.

Friedman JM , Birch PH : Type 1 neurofibromatosis: A descriptive analysis of the disorders in 1,728 patients. Am J Med Genet 1997;70:138—143.

13.

Samuelsson B. , Samuelsson S. : Neurofibromatosis in Gothenburg, Sweden. Background, study design and epidemiology. Neurofibromatosis 1989;2:6—22.

14.

Creange A. , Zeller J. , Rostaing-Rigattieri S. , et al: Neurological complications of neurofibromatosis type 1 in adulthood . Brain 1999;122:473—481.

15.

Hughes Rac : Neurological complications of neurofibromatosis 1, in Huson SM , Hughes RAC (eds): The Neurofibromatoses. A Pathogenetic and Clinical Overview . London, Chapman and Hall, 1994, 204—232.

16.

Barkovich AJ : Pediatric Neuroimaging. Philadelphia, Lippincott, Wolliams & Wilkins, 2002.

17.

Zhu Y. , Romero MI , Ghosh P. , et al: Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 2001;15:859—876.

18.

Li C. , Cheng Y. , Gutmann DA , et al: Differential localization of the neurofibromatosis 1 (NF1) gene product neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. Dev Brain Res 2001;130:231—248.

19.

Lakkis MM , Golden JA , O'Shea Ks , et al: Neurofibromin deficiency in mice causes axencephaly is a modifier for splotch neural tube defects. Dev Biol 1999;212:80—92.

20.

Rosman NP , Pearce J. : The brain in multiple neurofibromatosis (von Recklinghausen's disease): A suggested neuropathological basis for the associated mental defect. Brain 1967;14:829—840.

21.

Kato M. , Takaschima S. , Houdou S. , et al: Cerebellar leptomeningeal heterotopia in neurofibromatosis type 1. Clin Neuropathol 1995;14:175—178.

22.

Balestri P. , Lucignani G. , Fois A. , et al: Cerebral glucose metabolism in neurofibromatosis type 1 assessed with [18F]-2-fluoro-2-deoxy-D-glucose and PET. J Neurol Neurosurg Psychiatry 1994 ; 57:1479—1483.